Pharmaceutical Science Advances最新文献

{"title":"Progresses in the study of polysaccharide from medicinal plants of the Asclepiadaceae family","authors":"He Xiao ,&nbsp;Ziqing Zeng ,&nbsp;Wenjie Jiang","doi":"10.1016/j.pscia.2024.100045","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100045","url":null,"abstract":"<div><p>Medicinal plants from the Asclepiadaceae family, such as Luo Mo (<em>Metaplexis japonica</em> Makino), Xu Changqing (<em>Cynanchum paniculatum</em>), and Bai Wei (<em>Cynanchum atratum</em> Bge.), have long been staples in Traditional Chinese Medicine (TCM) due to their wide range of pharmacological activities (Su et al., 2021) [1]. These beneficial properties are largely attributed to compounds like saponins, alkaloids, and polysaccharides. Polysaccharides, in particular, are vital components in TCM and have garnered increasing attention for their diverse therapeutic effects. Polysaccharides from Asclepiadaceae plants are reported to exhibit a variety of pharmacological activities, including anti-radiation, anti-tumor, anti-fatigue, antioxidant, anti-hyperlipidemic, immune-boosting, and liver-protective effects. These polysaccharides have complex structures made up of different monosaccharides, contributing to their wide range of activities. In this review, we provide a comprehensive summary of the isolation, purification, structural characterization, and pharmacological activities of polysaccharides from medicinal plants in the Asclepiadaceae family. We begin by outlining the methods used for the extraction, isolation, and purification of these polysaccharides. Next, we delve into the pharmacological activities of the isolated polysaccharides. Finally, we discuss the potential clinical applications of these polysaccharides in treating various diseases and highlight areas that require further investigation.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100045"},"PeriodicalIF":0.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000114/pdfft?md5=d3e3439805917f3195d27ad1e679cd87&pid=1-s2.0-S2773216924000114-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141594753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fuel-propelled nanomotors for acute kidney injury applications","authors":"Weixin Wang ,&nbsp;Rui Gao ,&nbsp;Lin Zhang ,&nbsp;Zhongchao Wang ,&nbsp;Jiahui Sun ,&nbsp;Lei Luo ,&nbsp;Min Pan ,&nbsp;Miaofang Hong ,&nbsp;Jianming Wu ,&nbsp;Qibing Mei ,&nbsp;Ke Tong ,&nbsp;Yini Wang ,&nbsp;Lingyan Qiao ,&nbsp;Fei Tong","doi":"10.1016/j.pscia.2024.100044","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100044","url":null,"abstract":"<div><p>Acute kidney injury (AKI) is characterized by a rapid loss of renal metabolic function and a high mortality rate. Although significant progress has been made in developing targeted drugs for AKI treatment, issues such as inadequate antioxidant effects and poor renal enrichment efficiency remain. Nanomotors can enhance drug delivery efficiency in AKI treatments through self-propulsion in the microenvironment or via external stimuli. We reviewed recent progress in the targeted treatment of AKI with nanomotors, focusing on their contribution to targeted drug delivery at different stages and combined treatments. Current limitations and future development directions are also discussed.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100044"},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000102/pdfft?md5=4504c164042e6d4a1599cfcc3339045c&pid=1-s2.0-S2773216924000102-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141594752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible hemoglobin enhancing effect of phytol in methotrexate-induced folate deficient Swiss albino mice: In vivo and in silico studies","authors":"Muhammad Torequl Islam ,&nbsp;Raihan Chowdhury ,&nbsp;Md Sakib Al Hasan ,&nbsp;Salehin Sheikh ,&nbsp;Md Shimul Bhuia ,&nbsp;Sumaya Akter Bithi ,&nbsp;Most Israt Jahan Oni ,&nbsp;Mehedi Hasan Bappi ,&nbsp;Siddique Akber Ansari ,&nbsp;Elaine C.P. Lucetti ,&nbsp;Catarina M. Tahim ,&nbsp;Henrique Douglas Melo Coutinho ,&nbsp;Irfan Aamer Ansari","doi":"10.1016/j.pscia.2024.100043","DOIUrl":"10.1016/j.pscia.2024.100043","url":null,"abstract":"<div><p>The diterpenoid phytol is evidently acting against anemia in experimental animals. However, the molecular mechanisms behind this issue are yet to be discovered. This study aimed to evaluate phytol's effect on methotrexate-induced folate-deficient animals through in vivo and in silico studies. For this, a total of thirty adult male Swiss albino mice were randomly divided into six different groups, namely the normal control (vehicle), the negative control (folate deficiency inducer, methotrexate 3 ​mg/kg), the standard (folic acid 1.5 ​mg/kg), two test groups comprising phytol 25 and 50 ​mg/kg, and a combined group composed of the standard and highest test doses of phytol. Except for the vehicle, all groups were treated with methotrexate for the first 3 days (once/day) to induce folate deficiency. Then followed by the respective treatment once a day for 3 days. Hemoglobin (Hb) level was measured from the peripheral blood (by tail cutting) on days 1st (before treatment), 4th (after methotrexate treatment), and 7th (after treatment). On the other hand, the computational studies were performed by PyMol, PyRex, Discovery Studio, and other complementary tools. Findings suggest that phytol significantly (<em>p</em> ​&lt; ​0.05) augmented Hb levels that are altered by methotrexate-induced reduction of Hb levels in animals dose-dependently. The combination also augmented Hb levels in animals; however, its effect was slightly lower than the individual groups (standard and test). In the in silico study, phytol showed good binding capacity (binding energy: −7.0 ​kcal/mol) with dihydrofolate reductase (DHFR). In conclusion, phytol may act against folate deficiency by altering methotrexate's impacts in animals, possibly through interacting with DHFR. Further validated research is necessary to develop phytol as an anti-anemia drug in the near future.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100043"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000096/pdfft?md5=bfaea545e629e34b31944f3178097e2e&pid=1-s2.0-S2773216924000096-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141407753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytochemical analysis and evaluation of the antibacterial and antibiotic potentiation activities of the aqueous extract of Cordia oncocalyx Allemão (Boraginaceae)","authors":"José Thyalisson da Costa Silva ,&nbsp;José Jailson Lima Bezerra ,&nbsp;Talysson Felismino Moura ,&nbsp;Rafael Pereira da Cruz ,&nbsp;Maraiza Gregorio de Oliveira ,&nbsp;Adrielle Rodrigues Costa ,&nbsp;Felicidade Caroline Rodrigues ,&nbsp;João Arthur de Oliveira Borges ,&nbsp;Terezinha Raila Ramos de Sousa ,&nbsp;Maria Flaviana Bezerra Morais-Braga ,&nbsp;Henrique Douglas Melo Coutinho ,&nbsp;José Weverton Almeida-Bezerra","doi":"10.1016/j.pscia.2024.100042","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100042","url":null,"abstract":"<div><p>The global antibiotic resistance crisis highlights the inappropriate use of medicines by the population and the lack of development of new antimicrobial agents. According to various studies, natural products are promising alternatives for combating bacterial resistance and treating infectious diseases. Accordingly, the present study aimed to analyze the chemical composition and evaluate the antibacterial and antibiotic potential of an aqueous extract of <em>Cordia oncocalyx</em> Allemão (AECO). Phytochemical analyses were performed using high-performance liquid chromatography equipped with a diode array detector (HPLC-DAD). The minimum inhibitory concentration (MIC) was used to evaluate the antibacterial activity of <em>C. oncocalyx</em> against conventional and multidrug-resistant (MDR) bacterial strains (<em>Escherichia coli, Pseudomonas aeruginosa</em>, and <em>Staphylococcus aureus</em>). According to HPLC-DAD analysis, the following compounds could be identified in the aqueous extract of <em>C. oncocalyx</em>: luteolin (3.07 ± 0.04 mg/g), caffeic acid (1.05 ± 0.03 mg/g), ellagic acid (0.62 ± 0.05 mg/g), and quercetin (0.58 ± 0.01). AECO did not exhibit antibacterial activity when administered alone (MIC &gt;512 μg/mL). However, when combined with gentamicin, ampicillin, and norfloxacin, AECO potentiated the action of these antibiotics against the multi-resistant strains of <em>P. aeruginosa</em> and <em>S. aureus</em>. Although clinical relevance was not revealed by the <em>in vitro</em> tests against pathogenic bacteria, AECO can combined with commercial antibiotics to improve their antibacterial effects. Future studies focusing on the mechanisms of action of the compounds isolated from <em>C. oncocalyx</em> and toxicological tests are fundamental.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000084/pdfft?md5=3b5fd055b0939ece2db4bd95252fb6b5&pid=1-s2.0-S2773216924000084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rational design of siRNA-based delivery systems for effective treatment of brain diseases","authors":"Dailin Lu ,&nbsp;Yonghang Sun ,&nbsp;Yuxia Luan,&nbsp;Wenxiu He","doi":"10.1016/j.pscia.2024.100041","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100041","url":null,"abstract":"<div><p>Effective clinical methods are urgently required to treat brain diseases. Small interfering RNAs (siRNAs) are promising in the treatment of brain diseases because of their ability to target and specifically silence genes associated with disease progression. However, their effectiveness is hindered by physiological barriers such as enzymatic degradation, the blood-brain barrier, and the blood-brain tumor barrier, severely restricting them from reaching the desired target sites. The development of nanotechnology has made the effective delivery of siRNAs to the brain possible. This is accomplished by encapsulating siRNAs in cationic polymers, liposomes, or micelles to improve their stability and targeting efficiency. In this review, we first analyzed the limitations of siRNA delivery in brain diseases such as brain tumors, stroke, and neurodegenerative diseases. Next, we summarized how nanotechnology can offer a solution by enabling effective siRNA delivery to the brain and improving the intracellular transfection efficiency of siRNA. Finally, we discussed the challenges and future advances of siRNA-based delivery systems to facilitate their clinical translation. This review emphasizes the importance of overcoming physiological barriers associated with siRNA delivery and highlights recent advances in the rational design of siRNA-based delivery systems for the effective treatment of brain diseases.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000072/pdfft?md5=8c06ff13b971cd909de39b050bf76bc3&pid=1-s2.0-S2773216924000072-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WN1703 alleviates gout symptoms via inflammatory signaling pathways in an acute gout rat model","authors":"Fuyao Liu,&nbsp;Xiaodan Lu,&nbsp;Lei Zhang,&nbsp;Jing Li","doi":"10.1016/j.pscia.2024.100039","DOIUrl":"10.1016/j.pscia.2024.100039","url":null,"abstract":"<div><p>We previously synthesized the xanthine oxidoreductase (XOR) inhibitor WN1703. In addition to showing XOR inhibitory effects, WN1703 also showed anti-inflammatory effects in a rat hyperuricemia model. Here, we studied WN1703's anti-inflammatory effects on gout and explored the underlying mechanisms. Tohoku Hospital Pediatrics-1 (THP-1) cells were stimulated by lipopolysaccharide/interferon-γ/monosodium urate (MSU). The levels of inflammatory cytokines in the supernatant and protein expression in THP-1 cells were detected using enzyme-linked immunosorbent assay (ELISA) kits and western blotting, respectively, to verify the inhibitory effects of WN1703 and its mechanism. Potassium oxonate, hypoxanthine, and MSU were administered to establish a hyperuricemia rat model complicated by acute gouty arthritis. At 1–24 h after MSU injection, the degree of ankle swelling was recorded to compare the anti-inflammatory effects at each time point. The potential mechanism was further explored using immunohistochemistry and ELISA. WN1703 significantly downregulated expression of nucleotide-binding oligomerization domain-like receptor thermal protein domain associated protein 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), caspase-1, toll-like receptor-4 (TLR4), myeloid differentiation primary response protein 88 (MyD88), nuclear factor-kappa B (NF-κB), and relevant cytokine levels in THP-1 cells. Identical doses of WN1703 and febuxostat had comparable effects on these proteins and cytokines. In the gout rats, the same dose of WN1703 and febuxostat showed equivalent inhibitory effects on NLRP3, ASC, and NF-κB; however, WN1703 showed weaker impacts on alleviating ankle swelling than febuxostat showed. In conclusion, WN1703 showed significant anti-inflammatory effects in hyperuricemic rats with acute gout. Such effects were related to the inhibition of the NLRP3/ASC/Caspase-1 and TLR4/MyD88/NF-κB signaling pathways, thereby downregulating inflammation-related protein expression and decreasing inflammatory cytokine secretion.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100039"},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000059/pdfft?md5=827dd9ffb0fdf9527799da1e715215a1&pid=1-s2.0-S2773216924000059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140401673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent progresses in combination cancer therapy using cyanine dye-based nanoparticles","authors":"Qian An ,&nbsp;Si-Rui Xiang ,&nbsp;You-Quan Zou","doi":"10.1016/j.pscia.2024.100040","DOIUrl":"10.1016/j.pscia.2024.100040","url":null,"abstract":"<div><p>Surgical resection, radiotherapy, and chemotherapy are traditional methods for cancer treatment. With the development of materials science, photodynamic, photothermal, and sonodynamic therapies have been established over the past few years. Despite these advances, the development of novel and efficient cancer treatment protocols remains highly desirable. Recently, combination therapy has emerged as a powerful tool for achieving this goal. In this context, cyanine-nanoparticles have attracted considerable interest. Cyanine dyes have high molar absorptivity, narrow absorption/emission bands, and also excellent biocompatibility. This has meant that they have been widely used in biomedical imaging and therapy. Cyanine nanoparticles assembled from cyanine dyes and amphiphilic polymers or liposomes are endowed with high biocompatibility and long-term circulation for cancer combination therapy. A plethora of cyanine–nanoparticle-based combination therapy systems have been reported, and research in this discipline continues to expand. In this review, we aim to summarize recent advances in the combination therapy of cancers using cyanine nanoparticles over the last five years (i.e., from 2018 to 2023), with an emphasis on the structures of cyanine dyes, design concepts, and combination strategies. Personal insights and challenges in this field are also discussed. We expect that this review will inspire creative progress in combination therapies based on cyanine nanoparticles and facilitate the investigation of future clinical applications.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000060/pdfft?md5=dd24426ea65b5644321f1dc848ea95f1&pid=1-s2.0-S2773216924000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140406373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The most recent advances in liquisolid technology: Perspectives in the pharmaceutical industry","authors":"Yaseen Hussain ,&nbsp;Jinghao Cui ,&nbsp;Amos Dormocara ,&nbsp;Haroon Khan","doi":"10.1016/j.pscia.2024.100038","DOIUrl":"10.1016/j.pscia.2024.100038","url":null,"abstract":"<div><p>Hydrophobic drugs exhibit altered bioavailability and pose other challenges at an industrial level due to their poor solubility and dissolution rates. In addition, poor flowability, compressibility, complex dosing schedules, and light-sensitivity problems associated with hydrophobic drugs have led to poor patient compliance. To overcome these problems at an industrial level, the liquid-solid technique is a promising approach for tackling such challenges. This study outlines the prementioned challenges related to hydrophobic drug candidates and introduces the liquisolid technique as a potential alternative using non-volatile water-miscible solvents, carrier agents, coating substances, and their subsequent applications in the pharmaceutical industry. Furthermore, this study highlights the role of liquisolid technology in achieving sustained-release kinetics, emphasizing its benefits in minimizing pH changes in drug release and enhancing photostability. The study aimed to explore the liquisolid technique as an important tool for improving drug delivery, overcoming solubility issues, and optimizing therapeutic outcomes. In addition, this manuscript holds significant importance by highlighting the applications and recent advances in liquisolid technology, focusing on industrial-level applications. Moreover, it is impressive that such a technique offers improved formulation options to enhance the safety and efficacy of therapy. Overall, this study serves as a valuable resource for researchers to overcome formulation challenges and optimize drug delivery in the pharmaceutical industry.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000047/pdfft?md5=28e7fad4f3931f73de3aa176469437b7&pid=1-s2.0-S2773216924000047-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140273362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and research progress of oncolytic virus","authors":"Yingyu Chen ,&nbsp;Mengyuan Tao ,&nbsp;Xuwei Wu ,&nbsp;Zheng Tang ,&nbsp;Yinfu Zhu ,&nbsp;Kunxiang Gong ,&nbsp;Yinger Huang ,&nbsp;Wenbo Hao","doi":"10.1016/j.pscia.2024.100037","DOIUrl":"10.1016/j.pscia.2024.100037","url":null,"abstract":"<div><p>Oncolytic viruses (OVs) are natural or genetically recombinant viruses that selectively infect and kill tumor cells without affecting normal cell growth. As a novel type of immunotherapy, OVs have been shown to activate antitumor immune responses, regulate the tumor microenvironment, and enhance the efficacy of immune checkpoint inhibitors. In this review article, we discuss the latest research on the characteristics, antitumor mechanisms, and status of OV research. In terms of mechanism of action, after targeting tumor cells, OVs not only directly lyse tumor cells but also exert antitumor effects through indirect approaches. As an emerging cancer treatment, OVs face challenges that need to be overcome. Finally, we summarize the challenges and prospects for the future application of OVs.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000035/pdfft?md5=d88b2383a920ee72888d00114bd11969&pid=1-s2.0-S2773216924000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140275801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of lycorine hydrochloride against diabetic nephropathy in high-fat diet and streptozotocin-induced diabetic mice","authors":"Kai-Li Fang ,&nbsp;Xin-Yu Qi ,&nbsp;Qing-Tong Han ,&nbsp;Lu-Zhou Chen ,&nbsp;Xiao-Ning Wang ,&nbsp;Zhen-Peng Xu ,&nbsp;Lu-Qing Shang ,&nbsp;Tao Shen","doi":"10.1016/j.pscia.2024.100035","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100035","url":null,"abstract":"<div><p>Diabetic nephropathy (DN) poses a significant risk to individuals with diabetes. Inflammation plays a crucial role in DN pathogenesis. Lycorine hydrochloride (LH) is derived from <em>Lycoris radiata</em> (L'Hér.). This herb has been identified as a potent anti-inflammatory molecule. Further studies indicated that LH displayed therapeutic potential against metabolic disorders, renal dysfunction, and fibrosis in a high-fat diet and streptozotocin-induced (HFD/STZ)-induced DN mouse model. Mechanistically, LH mitigated renal inflammation in DN mice by targeting NF-κB pathways and the NLRP3 inflammasome verified by <em>in vivo</em> study. <em>In vitro</em>, LH inhibited NLRP3 inflammasome activation induced by nigericin (Ng), monosodium urate (MSU), and ATP, reduced caspase-1 activation, and IL-1β release. Additionally, LH suppressed the NF-κB IS-induced activation, prevented nuclear translocation of NF-κB, and subsequently reduced the expression of downstream proteins COX2 and iNOS. Collectively, these results indicated that LH primarily improved hyperglycemia-induced renal function by reducing inflammation by targeting NF-κB and NLRP3 inflammasome, implying it is a promising therapeutic agent for DN.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100035"},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000011/pdfft?md5=e5fb7692c1c50492d880fd4f179372d7&pid=1-s2.0-S2773216924000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}